Advanced Malignancies | Norton Healthcare

As we continue to seek to protect our patients, face masks are required in patient settings such as hospitals, doctors’ offices and medical centers.

Indication: Advanced Malignancies

An open-label, multicenter Phase I dose escalation study to characterize safety, tolerability, preliminary antitumor activity, pharmacokinetics and maximum tolerated dose of VIP152 (BAY 1251152) in subjects with advanced cancer

Sub-indication: Miscellaneous Malignancies

Study Type: Drug Study

Principal Investigator: Don Stevens, M.D.
Norton Cancer Institute

Sponsor: Sponsor: Vincerx Pharma, Inc

Email for more information: MISC-NCIResearch@Nortonhealthcare.org Heme-NCIResearch@nortonhealthcare.org

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.

As we continue to seek to protect our patients, face masks are required in patient settings such as hospitals, doctors’ offices and medical centers.

Advanced Malignancies Clinical Trial

Schedule an Appointment